Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H9NOSe |
Molecular Weight | 274.18 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1N([Se]C2=CC=CC=C12)C3=CC=CC=C3
InChI
InChIKey=DYEFUKCXAQOFHX-UHFFFAOYSA-N
InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H
Molecular Formula | C13H9NOSe |
Molecular Weight | 274.18 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Ebselen is a small molecule mimic and inducer of glutathione peroxidase activity and possesses antioxidant and anti-inflammatory properties. This drug has been investigated in phase II clinical trials for the treatment of Meniere's disease, bipolar disorder and in the prevention of hearing loss. Besides, experiments on mice have shown that ZIKV infection could be on the list for potential use of ebselen. It alleviates testicular pathology in mice with Zika virus infection and prevents its sexual transmission. Ebselen has various mechanisms of action. It binds to the N-terminal domain of soluble epoxide hydrolase and chemically reacts with the enzyme to quickly and irreversibly inhibit one of the enzymes' activity: phosphatase (Nterm-phos). Besides, ebselen inhibits inositol monophosphatase and thus exhibits lithium-like on human central nervous system (CNS) function. In addition, ebselen inhibits the G4 isoform of acetylcholinesterase. It is a well-known relationship between the cholinergic system and learning, memory and other common cognitive processes, thus ebselen can be studied for the treatment of memory impairment diseases.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P34913|||Q9HBJ2 Gene ID: 2053.0 Gene Symbol: EPHX2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23219563 |
550.0 nM [Ki] | ||
Target ID: P22303|||Q53F46 Gene ID: 43.0 Gene Symbol: ACHE Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/29405440 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30.3 ng/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
70.3 ng/mL |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
67.5 ng/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
83.4 ng/mL |
1600 mg single, oral dose: 1600 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
546.31 ng × h/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
710.1 ng × h/mL |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
883.15 ng × h/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
992.64 ng × h/mL |
1600 mg single, oral dose: 1600 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.42 h |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
14.4 h |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
12.1 h |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
|
16.7 h |
1600 mg single, oral dose: 1600 mg route of administration: Oral experiment type: SINGLE co-administered: |
EBSELEN plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
PZ-51 (Ebselen) in vivo protection against adriamycin-induced mouse cardiac and hepatic lipid peroxidation and toxicity. | 1992 Aug 18 |
|
Molecular actions of ebselen--an antiinflammatory antioxidant. | 1995 Oct |
|
Cellular factors as alternative targets for inhibition of HIV-1. | 1997 Feb |
|
Inhibition of ebselen on aflatoxin B(1)-induced hepatocarcinogenesis in Fischer 344 rats. | 2000 Dec |
|
Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. | 2000 Feb 18 |
|
Anti-oxidant ebselen causes the resolution of experimentally induced hepatic fibrosis in rats. | 2001 Nov |
|
Activation of matrix metalloproteinase-2 by overexpression of manganese superoxide dismutase in human breast cancer MCF-7 cells involves reactive oxygen species. | 2002 Jun 7 |
|
Functionalized alkyl and aryl diselenides as antimicrobial and antiviral agents: synthesis and properties. | 2003 Dec |
|
An inducible nitric oxide synthase-luciferase reporter system for in vivo testing of anti-inflammatory compounds in transgenic mice. | 2003 Jun 15 |
|
Selenium-containing compounds attenuate peroxynitrite-mediated NF-kappaB and AP-1 activation and interleukin-8 gene and protein expression in human leukocytes. | 2003 Nov 1 |
|
Renal and hepatic ALA-D activity and selected oxidative stress parameters of rats exposed to inorganic mercury and organoselenium compounds. | 2004 Jan |
|
Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain. | 2005 Jul |
|
Up-regulation of heme oxygenase provides vascular protection in an animal model of diabetes through its antioxidant and antiapoptotic effects. | 2006 Dec |
|
Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron injury and amelioration by ebselen. | 2006 Jul |
|
Enhancement of tumor invasion depends on transdifferentiation of skin fibroblasts mediated by reactive oxygen species. | 2006 Jul 1 |
|
Oral pretreatment with ebselen enhances heat shock protein 72 expression and reduces myocardial infarct size. | 2006 Nov |
|
Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. | 2006 Oct 1 |
|
Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake. | 2006 Sep |
|
The protective mechanism of antioxidants in cadmium-induced ototoxicity in vitro and in vivo. | 2008 Jul |
|
Mitochondria-derived reactive oxygen species mediate heme oxygenase-1 expression in sheared endothelial cells. | 2009 Apr |
|
A superoxide anion-scavenger, 1,3-selenazolidin-4-one suppresses serum deprivation-induced apoptosis in PC12 cells by activating MAP kinase. | 2011 Dec 15 |
|
Antimalarial screening via large-scale purification of Plasmodium falciparum Ca2+-ATPase 6 and in vitro studies. | 2013 Nov |
|
The seleno-organic compound ebselen impairs mitochondrial physiology and induces cell death in AR42J cells. | 2014 Sep 17 |
Patents
Sample Use Guides
Bipolar Disorder: ebselen capsules each containing 200mg taken orally twice a day for 3 weeks
Meniere's Disease: 200, 400 or 600 mg of drug bid po x 21d
hearing loss: 400 mg twice daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29405440
ebselen at concentrations equal or higher than 10 µM inhibited the activity of cortical and hippocampal G4/acethylcholinesterase (AChE), but not G1/AChE isoform.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:11:21 GMT 2023
by
admin
on
Sat Dec 16 17:11:21 GMT 2023
|
Record UNII |
40X2P7DPGH
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1323
Created by
admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
|
||
|
NCI_THESAURUS |
C275
Created by
admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C65503
Created by
admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
|
PRIMARY | |||
|
100000080483
Created by
admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
|
PRIMARY | |||
|
77543
Created by
admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
|
PRIMARY | |||
|
40X2P7DPGH
Created by
admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
|
PRIMARY | |||
|
60940-34-3
Created by
admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
|
PRIMARY | |||
|
DTXSID7045150
Created by
admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
|
PRIMARY | |||
|
639762
Created by
admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
|
PRIMARY | |||
|
757883
Created by
admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
|
PRIMARY | |||
|
C042986
Created by
admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
|
PRIMARY | |||
|
5475
Created by
admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
|
PRIMARY | |||
|
EBSELEN
Created by
admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
|
PRIMARY | |||
|
DB12610
Created by
admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
|
PRIMARY | |||
|
SUB06439MIG
Created by
admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
|
PRIMARY | |||
|
m4803
Created by
admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
|
PRIMARY | Merck Index | ||
|
3194
Created by
admin on Sat Dec 16 17:11:21 GMT 2023 , Edited by admin on Sat Dec 16 17:11:21 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |